Presentation is loading. Please wait.

Presentation is loading. Please wait.

In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew.

Published byMarie-Ange Desroches Modified over 5 years ago

Similar presentations

Presentation on theme: "In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew."— Presentation transcript:

1 In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew D. Linden, Bracken Babula, Youfu Li, Marc R. Barnard, Chinara Tate, Kanika Mathur, Andrew L. Frelinger, and Alan D. Michelson Blood Volume 119(17): April 26, 2012 ©2012 by American Society of Hematology

2 Platelet parameters in healthy controls and in patients with ITP at 0, 7, and 28 days of eltrombopag treatment. Platelet parameters in healthy controls and in patients with ITP at 0, 7, and 28 days of eltrombopag treatment. (A) Platelet count, (B) mean platelet volume (MPV), (C) immature platelet fraction (IPF) %, and (D) absolute immature platelet fraction (AIPF). Data are mean ± SEM (*P < .05; **P < .02; ***P < .001). Bethan Psaila et al. Blood 2012;119: ©2012 by American Society of Hematology

3 Platelet parameters in responders to eltrombopag treatment.
Platelet parameters in responders to eltrombopag treatment. (A) Platelet count, (B) mean platelet volume (MPV), (C) immature platelet fraction (IPF) %, and (D) absolute immature platelet fraction (AIPF). Responders (black columns) and nonresponders (gray columns). Data are mean ± SEM (*P < .05; **P < .02; ***P < .001). Bethan Psaila et al. Blood 2012;119: ©2012 by American Society of Hematology

4 Platelet surface expression of activation markers in controls and ITP patients at days 0, 7, and 28 of eltrombopag treatment with no added agonist and in response to low and high dose ADP and TRAP stimulation. Platelet surface expression of activation markers in controls and ITP patients at days 0, 7, and 28 of eltrombopag treatment with no added agonist and in response to low and high dose ADP and TRAP stimulation. (A) Activated GPIIb/IIIa (PAC-1), (B) P-selectin, and (C) GPIb. C indicates healthy controls; D0, ITP patients pretreatment with eltrombopag; and D7 and D28, 7 and 28 days after initiation of eltrombopag treatment in ITP patients. Black-capped bars indicate unpaired (ITP at baseline vs controls) and gray bars indicate pairwise comparisons (ITP patients at different study days). Data are mean ± SEM (*P < .05; **P < .02; ***P < .001). Bethan Psaila et al. Blood 2012;119: ©2012 by American Society of Hematology

5 Platelet surface markers of activation in responders and nonresponders to eltrombopag treatment with no added agonist and in response to low and high dose ADP and TRAP stimulation. Platelet surface markers of activation in responders and nonresponders to eltrombopag treatment with no added agonist and in response to low and high dose ADP and TRAP stimulation. (A-C) Responders and (D-F) nonresponders. (A,D) Activated GPIIb/IIIa (PAC-1), (B,E) P-selectin, and (C,F) GPIb. C indicates healthy controls; D0, ITP patients pretreatment with eltrombopag; D7 and D28, 7 and 28 days after initiation of eltrombopag treatment in ITP patients. Data are mean ± SEM (*P < .05; **P < .02; ***P < .001). Bethan Psaila et al. Blood 2012;119: ©2012 by American Society of Hematology

6 Platelet surface markers of activation in controls following in vitro manipulation of platelet counts. Platelet surface markers of activation in controls following in vitro manipulation of platelet counts. (A) Activated GPIIb/IIIa, (B) P-selectin, and (C) GPIb. Data are mean ± SEM, n = 5 (*P < .05, **P < .02) for agonist-induced platelet integrin expression in thrombocytopenic samples compared with that at “normal” platelet counts (ie, 175 × 109/L). Bethan Psaila et al. Blood 2012;119: ©2012 by American Society of Hematology

Download ppt "In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew."

Similar presentations

The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo by Vicky Louise Morrison, Matthew MacPherson,

The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo by Vicky Louise Morrison, Matthew MacPherson,
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
CD8 + T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia by Li Ma, Elisa Simpson,

CD8 + T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia by Li Ma, Elisa Simpson,
Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated.

Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated.
Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are.

Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are.
Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts by Esther R. van Bladel,

Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts by Esther R. van Bladel,
Activation of αIIbβ3 is a sufficient but also an imperative prerequisite for activation of α2β1 on platelets by Gerlinde R. Van de Walle, Anne Schoolmeester,

Activation of αIIbβ3 is a sufficient but also an imperative prerequisite for activation of α2β1 on platelets by Gerlinde R. Van de Walle, Anne Schoolmeester,
by Matt W. Goschnick, Lai-Man Lau, Janet L. Wee, Yong S. Liu, P

by Matt W. Goschnick, Lai-Man Lau, Janet L. Wee, Yong S. Liu, P
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,

A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.

Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.
Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis.

Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis.
Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy by Frédéric Van Gool, Ari B. Molofsky, Malika.

Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy by Frédéric Van Gool, Ari B. Molofsky, Malika.
Triple play of H pylori in ITP

Triple play of H pylori in ITP
by Henrik Frederiksen, and Kai Schmidt

by Henrik Frederiksen, and Kai Schmidt
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel by Andy S.

Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel by Andy S.
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,

PRT , a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response by Andreas Rosenwald, Eric Y. Chuang,

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response by Andreas Rosenwald, Eric Y. Chuang,
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Similar presentations

Ads by Google